Cryosurgical ablation of unresectable hepatic metastases
Background and Objectives: Recent advancements in the technology of cryosurgery along with the development and refinement of intraoperative ultrasound have led to a feasible alternative for some patients with unresectable hepatic malignancy. This paper reports our first year's experience with c...
Gespeichert in:
Veröffentlicht in: | Journal of surgical oncology 1998-08, Vol.68 (4), p.242-245 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background and Objectives: Recent advancements in the technology of cryosurgery along with the development and refinement of intraoperative ultrasound have led to a feasible alternative for some patients with unresectable hepatic malignancy. This paper reports our first year's experience with cryosurgical ablation of unresectable hepatic malignancies.
Methods
From May 1996 to July 1997, 12 patients with colorectal hepatic metastases underwent exploration for possible resection and/or cryosurgery. At surgery, three patients had extensive disease and were not candidates for any surgical treatment, three underwent formal right hepatic lobectomy, five underwent a combination of resection and cryoablation, while one underwent cryoablation alone.
Results
In the six patients who received cryosurgery, the mean number of metastatic lesions was four (range 1–6). The mean number of lesions frozen was two (range 1–4) with a mean size of 2.5 cm. (range 1–5 cm). There were no intraoperative deaths and no major postoperative complications. All patients were discharged home in stable condition with a mean hospital stay of eight days (range 5–14 days). At a mean follow‐up of 17.3 months (range 10–22) three patients were alive with disease and three were disease free.
Conclusions
Cryosurgical ablation is a safe method of treating unresectable hepatic malignancies and it may extend survival in carefully selected patients. J. Surg. Oncol. 68:242–245, 1998. © 1998 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0022-4790 1096-9098 |
DOI: | 10.1002/(SICI)1096-9098(199808)68:4<242::AID-JSO7>3.0.CO;2-4 |